SINOMAB BIO-B

SinoMab Bioscience staged a strong rebound today, surging 20.4% to close at HKD 1.300, with an intraday range of 23.1% from HKD 1.080 to HKD 1.330. The rally was driven by multiple recent positive developments: an annual loss narrowing 43.3% YoY to RMB 105 million, first cohort dosing completion for SM17 subcutaneous injection in China, and China IND approval to expand SM17 into inflammatory bowel disease. In Q4, EPS loss narrowed 51.7% YoY to HKD 0.0226, and net loss shrank 39.0% YoY. The stock closed above its MA20 (HKD 1.129) but remains 65.4% below the 52-week high of HKD 3.76, with a YTD decline of 6.5% and PB of 3.2x. However, the MA60 at HKD 1.341 still sits above the current price, suggesting the recovery remains incomplete.